Starpharma Holdings Limited · ASX:SPL

Starpharma — PODD 2021

13 slides from Starpharma's conference presentation, Oct 28, 2021

  1. Slide 1: Enhancing drug delivery: DEP dendrimer platform

    Slide 1: Enhancing drug delivery: DEP dendrimer platform

    Enhancing drug delivery DEP® dendrimer platform Tony Eglezos VP Business Development PODD #PODD2021

  2. Slide 2: Important notice and disclaimer

    Slide 2: Important notice and disclaimer

    Important notice and disclaimer This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward- looking terminology such as “promising”, “plans”, “articipated’, “wil”, “project’, "beleve", “forecast”, “expected, “estimated,

  3. Slide 3: Starpharma's DEP strategy

    Slide 3: Starpharma's DEP strategy

    Starpharma’s DEP® strategy : “To leverage our proprietary dendrimer platform to build high value products and partnerships that address significant unmet need” PODD #PODD2021 3

  4. Slide 4: Partnering creates significant value and optionality

    Slide 4: Partnering creates significant value and optionality

    DEP® partnering creates significant value and optionality Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of drugs, creating multiple potential revenue streams and significant IP leverage PODD #PODD2021

  5. Slide 5: Preferential tumour accumulation enhanced benefits

    Slide 5: Preferential tumour accumulation enhanced benefits

    DEP® platform - preferential tumour accumulation enhanced benefits PODD #PODD2021 5

  6. Slide 6: DEP drug delivery platform enhances therapeutic and commercial value of drugs

    Slide 6: DEP drug delivery platform enhances therapeutic and commercial value of drugs

    Starpharma’s DEP® drug delivery platform enhances the therapeutic and commercial value of drugs PODD #PODD2021 6

  7. Slide 7: Technology platform with multiple commercial opportunities in oncology and beyond

    Slide 7: Technology platform with multiple commercial opportunities in oncology and beyond

    DEP® is a technology platform with multiple commercial opportunities in oncology and beyond PODD #PODD2021 7

  8. Slide 8: Internal oncology programs

    Slide 8: Internal oncology programs

    DEP® internal oncology programs Multiple clinical-stage assets with high commercial value potential PODD #PODD2021 8

  9. Slide 9: Drugs are ideal candidates for combination therapy

    Slide 9: Drugs are ideal candidates for combination therapy

    DEP® drugs are also ideal candidates for combination therapy- conventional, targeted and Immuno-Oncology approaches PODD #PODD2021 9

  10. Slide 10: Targeted DEP conjugates provide additional flexibility

    Slide 10: Targeted DEP conjugates provide additional flexibility

    Targeted DEP® conjugates provide additional flexibility PODD #PODD2021 10

  11. Slide 11: ADC / Radiotheranostic platform

    Slide 11: ADC / Radiotheranostic platform

    DEP® ADC / Radiotheranostic platform Flexibility in targeting approach – Flexibility in payload - Enhanced performance PODD These experiments were conducted in either a human ovarian cancer #PODD2021 (SKOV-3) or human prostate cancer (DU-145) mouse xenograft model 11

  12. Slide 12: Platform – significant optionality, therapeutic and commercial benefits

    Slide 12: Platform – significant optionality, therapeutic and commercial benefits

    DEP® platform – significant optionality, therapeutic and commercial benefits PODD #PODD2021

  13. Slide 13: Contact: Tony Eglezos, Starpharma

    Slide 13: Contact: Tony Eglezos, Starpharma

    www.starpharma.com Tony Eglezos VP Business Development Starpharma tony.eglezos@starpharma.com PODD #PODD2021

Source: Internet Archive copy of starpharma.com

More decks from Starpharma Holdings Limited

All 67 Starpharma decks